1
|
Komatsu G, Nonomura T, Sasaki M, Ishida Y, Arai S, Miyazaki T. AIM-deficient mouse fed a high-trans fat, high-cholesterol diet: a new animal model for nonalcoholic fatty liver disease. Exp Anim 2018; 68:147-158. [PMID: 30487357 PMCID: PMC6511520 DOI: 10.1538/expanim.18-0108] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Owing to changes in lifestyle, nonalcoholic fatty liver disease (NAFLD) is becoming a
common form of chronic liver injury. NAFLD comprises a wide variety of disease stages,
from simple steatosis to nonalcoholic steatohepatitis, which is a risk factor for the
development of hepatocellular carcinoma (HCC). Because animal models for NAFLD are needed
to investigate the precise pathogenesis, we aimed to establish a new mouse model employing
mice deficient for apoptosis inhibitor of macrophage (AIM−/−),
which exhibit accelerated lipid storage in the liver and high susceptibility to developing
HCC in response to a high-fat diet (HFD). AIM−/− mice were fed
the D09100301 diet, which contains 40 kcal% fat (trans fat 30 kcal%), high cholesterol
(2%), and 40 kcal% carbohydrates (20 kcal% fructose), and then features of obesity and
NAFLD including steatosis, inflammation, fibrosis, and HCC development were analyzed.
Although a comparable grade of liver steatosis was promoted in
AIM−/− mice by the D09100301 diet and the standard HFD (60
kcal% largely lard fat), significantly less lipid storage in visceral fat was observed
when the mice were fed the D09100301 diet. Accelerated liver inflammation was promoted by
the D09100301 diet compared with the HFD, but interestingly, HCC development was decreased
in mice fed the D09100301 diet. Our findings suggest that
AIM−/− mice fed the D09100301 diet exhibited a phenotype
that resembled nonobese NAFLD patients and thus could be an appropriate tool to study the
pathophysiology by which obesity increases the risk of HCC.
Collapse
Affiliation(s)
- Ginga Komatsu
- Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Toru Nonomura
- Research Division Pharmacology Group, New Drug Research Center Inc., 452-1 Toiso, Eniwa-shi, Hokkaido 061-1405, Japan
| | - Mai Sasaki
- Research Division Pathology Group, New Drug Research Center Inc., 452-1 Toiso, Eniwa-shi, Hokkaido 061-1405, Japan
| | - Yuki Ishida
- Research Division Pharmacology Group, New Drug Research Center Inc., 452-1 Toiso, Eniwa-shi, Hokkaido 061-1405, Japan
| | - Satoko Arai
- Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Toru Miyazaki
- Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.,AMED-CREST, Japan Agency for Medical Research and Development, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.,Max Planck-The University of Tokyo Center for Integrative Inflammology, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| |
Collapse
|